Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
Krishna Veeraraghavan Discusses Dealmaking Strategies With Law360
February 17, 2023
Corporate partner Krishna Veeraraghavan spoke with Law360 about ways to bolster dealmaking during an economic downturn. In “6 Ways Dealmakers Can Get Ahead In An Economic Slump,” published on February 17, Krishna discusses drafting ironclad contracts through strong negotiation tactics, which require a deep understanding of the client’s business and future events that may affect it, and extensive due diligence on financing.
Krishna also touches on why health care patents are set to become a significant area of M&A activity, among other topics. Several patents for key drugs are set to expire in the next few years, and drugmakers will need to introduce new drugs to stay profitable. A market shift in recent years has seen big drugmakers buy up smaller competitors creating their own drugs, Krishna notes.
"What they do now is they look to acquire companies who are doing the R&D on these assets," he says of large drug companies. "Right now a lot of the biotech companies [doing R&D] are trading at more affordable values, so I think you're going to see activity there."